Fig. 3: Survival analysis according to BCL2 super-expression in the entire cohort.

(A, B) EFS and OS of patients with low IPI (0–2). (C, D) EFS and OS of patients with high IPI (3–5). (E, F) EFS and OS of patients with GCB type DLBCL. (G, H) EFS and OS of patients with non-GCB type DLBCL. (I, J) EFS and OS of patients with stages 1–2. (K, L) EFS and OS of patients with stages 3–4.